Conversion from cytomegalovirus universal prophylaxis with valganciclovir to the preemptive monitoring approach to manage leukopenia after kidney or pancreas transplantation-Reference-Cited by-同舟云学术

Conversion from cytomegalovirus universal prophylaxis with valganciclovir to the preemptive monitoring approach to manage leukopenia after kidney or pancreas transplantation

Published:2021-04-27 Issue:4 Volume:23 Page:
ISSN:1398-2273
Container-title:Transplant Infectious Disease
language:en
Short-container-title:Transpl Infect Dis

Author:

Jorgenson Margaret R.¹^ORCID,Wong Cynthia¹,Descourouez Jillian L.¹,Saddler Christopher M.²^ORCID,Smith Jeannina A.²,Mandelbrot Didier A.²

Affiliation:

1. Department of Pharmacy University of Wisconsin Hospital and Clinics Madison WI USA

2. Department of Medicine University of Wisconsin‐Madison School of Medicine and Public HealthUniversity of Wisconsin Hospital and Clinics Madison WI USA

Publisher

Wiley

Subject

Infectious Diseases,Transplantation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/tid.13617

Reference27 articles.

1. The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation

2. Cytomegalovirus in solid organ transplant recipients—Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice

3. Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients: 1-Year Results of a Randomized Clinical Trial

4. Prophylactic Versus Preemptive Oral Valganciclovir for the Management of Cytomegalovirus Infection in Adult Renal Transplant Recipients

5. The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High-Risk Kidney Transplant Recipients

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Randomized Controlled Trial Comparing the Tolerability and Efficacy of Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients: Study Protocol (Maribavir IIR);2024-09-04

2. A call for cytomegalovirus stewardship initiatives in cardiothoracic transplant;JHLT Open;2024-05

3. Real world experience with conversion from valganciclovir to letermovir for cytomegalovirus prophylaxis: Letermovir reverses leukopenia and avoids mycophenolate dose reduction;Clinical Transplantation;2023-09-27

4. CMV antiviral stewardship: navigating obstacles to facilitate target attainment;Current Opinion in Organ Transplantation;2022-11-03

5. Cytomegalovirus antiviral stewardship in solid organ transplant recipients: A new gold standard;Transplant Infectious Disease;2022-10